@article{Liebau2002rIL18-38814,
  year={2002},
  title={rIL-18 triggered gene therapy based on a transduction with the IL-12 plasmid : a new option as immuno-therapy for osteosarcoma?},
  number={5},
  volume={22},
  issn={0250-7005},
  journal={Anticancer Research},
  pages={2559--2565},
  author={Liebau, Christian and Merk, Harry and Roesel, Christian and Schmidt, Sebastian and Karreman, Christiaan and Prisack, Johannes Bernd and Bojar, Hans and Baltzer, Axel W. A.}
}

<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/38814">
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/38814"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2017-05-09T11:11:11Z</dc:date>
    <dcterms:title>rIL-18 triggered gene therapy based on a transduction with the IL-12 plasmid : a new option as immuno-therapy for osteosarcoma?</dcterms:title>
    <dc:contributor>Roesel, Christian</dc:contributor>
    <dc:contributor>Merk, Harry</dc:contributor>
    <dc:contributor>Schmidt, Sebastian</dc:contributor>
    <dc:creator>Schmidt, Sebastian</dc:creator>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dc:creator>Liebau, Christian</dc:creator>
    <dc:creator>Bojar, Hans</dc:creator>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dcterms:issued>2002</dcterms:issued>
    <dc:language>eng</dc:language>
    <dc:creator>Karreman, Christiaan</dc:creator>
    <dc:contributor>Liebau, Christian</dc:contributor>
    <dc:contributor>Bojar, Hans</dc:contributor>
    <dc:contributor>Karreman, Christiaan</dc:contributor>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2017-05-09T11:11:11Z</dcterms:available>
    <dc:creator>Baltzer, Axel W. A.</dc:creator>
    <dc:contributor>Prisack, Johannes Bernd</dc:contributor>
    <dc:creator>Roesel, Christian</dc:creator>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:contributor>Baltzer, Axel W. A.</dc:contributor>
    <dcterms:abstract xml:lang="eng">Gene therapy is a promising new method to treat tumors locally. Immuno-therapy for treatment of osteosarcomas is one option for hopefully improving the survival rate of patients with this tumor. Transduction of OS cells with the pCMV-IL-12neo plasmid induced a significant increase in IFN-gamma expression by mononuclear cells. This is known to induce antitumor effects mediated by the immune system. In combination with an administration of rIL-18, the IFN-gamma increase was multiplied in a dose-dependent manner. This study demonstrated that osteosarcoma cells can be targeted effectively in vitro by plasmids encoding the IL-12 gene. Considering the synergistic pathways it is reasonable to combine a local, gene transfer based on IL-12 with a rIL-18 administration to trigger the potentially promising immuno-effects for adjuvant treatment of osteosarcomas.</dcterms:abstract>
    <dc:creator>Merk, Harry</dc:creator>
    <dc:creator>Prisack, Johannes Bernd</dc:creator>
  </rdf:Description>
</rdf:RDF>